This document summarizes the clinical examination of median nerve compressive neuropathies, including carpal tunnel syndrome, pronator syndrome, anterior interosseous nerve syndrome, and the ligament of Struthers. Key examination findings for each condition are described such as locations of pain, weakness, sensory deficits and positive provocation tests. Electrodiagnostic testing is recommended if surgery is being considered for carpal tunnel syndrome diagnosis.
anatomy of median nerve,course in arm and struthers ligament, branches in the forearm, carpal tunnel and course in hand, high and low median nerve injuries, principles of surgical management, pronator teres syndrome, anterior interosseous nerve syndrome, open and endoscopic carpal tunnel release
1.Anatomy
a.Course
b.Motor distribution
c.Sensory distribution
2.Common sites affected
3.Level of median nerve injury
4.Clinical feature with various test performed
5.Various syndromes related to median nerve
6.Treatment
7.Summary
anatomy of median nerve,course in arm and struthers ligament, branches in the forearm, carpal tunnel and course in hand, high and low median nerve injuries, principles of surgical management, pronator teres syndrome, anterior interosseous nerve syndrome, open and endoscopic carpal tunnel release
1.Anatomy
a.Course
b.Motor distribution
c.Sensory distribution
2.Common sites affected
3.Level of median nerve injury
4.Clinical feature with various test performed
5.Various syndromes related to median nerve
6.Treatment
7.Summary
An entrapment neuropathy is defined as a pressure or pressure-induced injury to a segment of a peripheral nerve secondary to anatomic or pathologic structures.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
2. Origin and Course
• The medial and lateral cords of the brachial plexus with contributions
from C6,7,8 and T1
• In the upper arm, the course of the median nerve is in close proximity
to the brachial artery, both of which pass along the anterior aspect of
the intermuscular septum on the medial side of the arm
• The median nerve and brachial artery enter the antecubital fossa
medial to the biceps brachii and superficial to the brachialis muscle,
then course through three successive arches as they enter the
forearm.
3. The Three Arches……
• The first arch is formed by the bicipital aponeurosis (lacertus fibrosis)
as it connects the biceps brachii to the flexor-pronator mass and the
ulna. The median nerve is superficial to the brachialis tendon, but
deep to the bicipital aponeurosis.
• The two heads of the pronator teres (PT) muscle form the second
arch. The median nerve lies superficial to the ulnar head and deep to
the humeral head.
• Finally, the median nerve travels between the humeroulnar and radial
heads of the flexor digitorumsuperficialis (FDS) muscle, under the
thick fibrous structure between them, known as the sublimis ridge.
4. In the Forearm …..
• In the forearm, the median nerve runs along the radial side of the
flexor digitorum profundus (FDP), deep to the FDS.
• The anterior interosseus nerve (AIN) branches from the median nerve
in the proximal half of the forearm. Terminates deep to the pronator
quadratus (PQ) muscle
• At approximately five cm proximal to the wrist crease, the median
nerve emerges superficially between the flexor carpi radialis (FCR)
tendon radially and the palmaris longus (PL) tendon ulnarly
5. In the Forearm, Wrist and Hand …..
• The palmar cutaneous branch of the median nerve arises approximately
five cm proximal to the distal wrist crease and passes outside of the carpal
tunnel
• Once in the hand, the thenar motor branch (or recurrent motor branch)
emerges radially.
• The median nerve goes on to divide into radial and ulnar divisions in the
plane between the flexor tendons (deep), and the palmar arch
(superficially).
• The radial division splits to form the common digital nerve to the thumb
and the proper digital nerve to the radial half of the index finger.
• The ulnar division splits to form the common digital nerves of the second
and third web spaces
6. Physical Examination
• The median nerve innervates muscles involved in forearm
pronation, wrist flexion, flexion of the digits, and thumb
opposition and abduction
• The median nerve carries sensory innervation from the
radial aspect of the palm via the palmar cutaneous branch,
and the volar surfaces of the thumb, index, middle fingers,
and the radial half of the ring finger.
• This sensory information is essential for fine motor tasks.
7. The Ligament of Struthers
• Approximately 1% of people have an accessory
condyle or supracondylar spur approximately five cm
proximal to the medial epicondyle of the humerus.
• The ligament of Struthers attaches this bony
prominence proximally to the medial epicondyle
distally.
• The median nerve is susceptible to compression as it
passes underneath this ligament along with the
brachial artery
8. •The patient will often complain of a deep aching pain
in the proximal forearm with an insidious onset,
hand weakness, and numbness in the median-nerve
distribution.
•On examination, this pain is often exacerbated with
testing of the PT and FCR. Worsening of symptoms
often occurs with repetitive pronation and
supination
•Frequently, weakness of muscles innervated by the
AIN is most prominent.
•A Tinel sign may be present proximal to the medial
epicondyle.
9. Pronator Syndrome
• Results from compression of the median nerve as it passes between
the 2 heads of the PT
• The patient often complains of aching discomfort in the forearm,
weakness in the hand, and numbness in the thumb and index finger
• Tenderness on palpation of the PT muscle is a common finding.
• A Tinel sign may be present in the antecubital fossa
• The PT muscle receives its innervation proximal to the site of
compression, and therefore might be the only muscle innervated by
the median nerve spared in this syndrome
10. A provocative maneuver
to test for pronator
syndrome is to apply
direct pressure in the area
of the PT with the
patient’s forearm
supinated. It is considered
positive if paresthesia is
reported in the median
nerve distribution within
one minute of
compression
11. Pronator Syndrome ……..
•Phalen’s test may be positive in 50%
patients with pronator syndrome
•Unlike CTS, a history of nocturnal
pain and/or numbness is rare
12. The Sublimus Arch
•The next possible site of compression along the
course of the median nerve is the sublimis arch
formed between the two heads of the FDS.
• Again, clinical findings are similar to those in
pronator syndrome, although pain exacerbated by
strong flexion of the proximal interphalangeal joints
of the index, long, ring, and little fingers is
suggestive of compression at the sublimis arch
rather than at the PT
13. Anterior interosseous nerve syndrome
• Vague proximal forearm pain and progressive loss in their ability to do
tasks requiring fine motor control and pinch, such as handwriting
• The patient will have weakness in the FDP to the index and middle
fingers and weakness in the PQ.
• Deficits in the flexor pollicis longus (FPL) and index-finger FDP result
in the inability to form the “OK” sign
• Sensibility is normal, as the AIN does not contain sensory fibers to the
hand
14. Symptoms of AIN
syndrome can be
provoked with
resisted elbow
flexion, resisted
forearm pronation,
and resisted finger
flexion
15. Carpal Tunnel Syndrome
• Patients predominantly complain of numbness and/or paresthesia in
the median-nerve distribution, rather than pain.
• These symptoms are typically worse at night and are improved with
shaking of the hand, known as the flick sign
• A history of dropping objects correlates with weakness of the
opponens pollicis and abductor pollicis brevis muscles.
• Atrophy of these thenar muscles represents advanced disease
16. Phalen wrist flexion
test = Maximal flexion
of wrists by opposing
dorsal surfaces of
hands = Reproduction
or exacerbation of
paresthesia or
numbness in median
nerve distribution
within 60 s
17. Durkin carpal
compression test =
Exert direct pressure at
or just proximal to the
carpal tunnel =
Reproduction or
exacerbation of
paresthesia or
numbness
in the median nerve
distribution within 60 s
18. Tinel Sign
Light tapping over the median
nerve at the wrist = Reproduction
or exacerbation of paresthesia in
the median nerve distribution
19. Static 2-point
discrimination
testing
Two points of various
distance are applied with
just enough pressure for
patient to appreciate the
stimulus = Inability to
distinguish 2 points 5 mm
apart
21. Ten test
A score (1–10) is reported by the patient
comparing an area of abnormal light
touch sensibility in the median nerve
distribution to an area of similar
innervation density with intact light touch
sensibility = Ratio less than one between
abnormal (scored 1–9) vs normal area
(scored 10). Allows examiner to track
changes over time
22. • The highest-level recommendation made by the AAOS group is to
obtain electrodiagnostic testing if clinical evaluation is positive and
surgical management is being considered.
• This recommendation remains controversial, as some investigators
claim electrodiagnostic tests do not change the probability of
diagnosing CTS in patients who are considered to have CTS based on
their history and physical examination alone